Coexistence of proangiogenic potential and increased MMP-9, TIMP-1, and TIMP-2 levels in the plasma of patients with critical limb ischemia.
The objective of this study was to assess the angiogenic potential expressed as a quotient of vascular endothelial growth factor A (VEGF-A), as an indicator of proangiogenic activity, and the circulating receptors (soluble VEGF receptor protein R1 (sVEGFR-1) and sVEGFR-2), as indicators of the effect of angiogenic inhibition, depending on the concentrations of matrix metalloproteinase 2 (MMP-2) and MMP-9 and their tissue inhibitor 1 (TIMP-1) and TIMP-2 in the plasma of patients with lower extremity artery disease (LEAD). These blood parameters in patients with intermittent claudication (IC) and critical limb ischemia (CLI) were compared for select clinical and biochemical features. Stimulation of angiogenesis in the plasma of individuals with LEAD was evident as indicated by the significant increase in VEGF-A concentration along with reduced inhibition depending on circulating receptors sVEGFR-1 and sVEGFR-2. Critical ischemia was associated with higher VEGF-A, MMP-9, TIMP-1, and TIMP-2 concentrations than in the case of IC.
['Wieczór|Radosław|R|', 'Wieczór|Anna Maria|AM|', 'Kulwas|Arleta|A|', 'Pulkowski|Grzegorz|G|', 'Budzyński|Jacek|J|', 'Rość|Danuta|D|']
D000368:Aged D020533:Angiogenesis Inhibitors D005260:Female D005786:Gene Expression Regulation D006801:Humans D007383:Intermittent Claudication D007511:Ischemia D035002:Lower Extremity D008297:Male D020780:Matrix Metalloproteinase 9 D008875:Middle Aged D009389:Neovascularization, Pathologic D019715:Tissue Inhibitor of Metalloproteinase-1 D019716:Tissue Inhibitor of Metalloproteinase-2 D042461:Vascular Endothelial Growth Factor A D040281:Vascular Endothelial Growth Factor Receptor-1 D040301:Vascular Endothelial Growth Factor Receptor-2
Critical limb ischemia Vascular endothelial growth factor Metalloproteinase Intermittent claudication